Current surgery for breast cancer

Future Oncology

Volumn 5, Issue 4, 2009, Pages 465-479

  Pockaj, Barbara A ^a   Gray, Richard J ^a  

^a MAYO CLINIC   (United States)

Author keywords

BRCA mutation; Breast; Breast cancer; Neoadjuvant chemotherapy; Pregnancy; Quality of life; Sentinel lymph node; Surgery

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; BRCA2 PROTEIN; GADOLINIUM; TAMOXIFEN;

ADJUVANT THERAPY; ASPIRATION BIOPSY; AXILLARY LYMPH NODE; BRACHYTHERAPY; BREAST BIOPSY; BREAST CANCER; BREAST RECONSTRUCTION; BREAST SURGERY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RISK; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; CONTINUING EDUCATION; DIAGNOSTIC PROCEDURE; DISEASE FREE SURVIVAL; ECHOMAMMOGRAPHY; EVIDENCE BASED MEDICINE; FAMILY HISTORY; GENE MUTATION; GENETIC COUNSELING; GENETIC SUSCEPTIBILITY; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAMMOGRAPHY; MASTECTOMY; MEDICAL DECISION MAKING; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARIECTOMY; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PATIENT CARE; PATIENT SELECTION; PLASTIC SURGERY; PREGNANCY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION SHIELD; REVIEW; RISK REDUCTION; SEGMENTAL MASTECTOMY; SENTINEL LYMPH NODE BIOPSY; STEREOTACTIC BIOPSY; SURGEON; SURGICAL TECHNIQUE; TERATOGENICITY; TUMOR LOCALIZATION; BREAST TUMOR; FEMALE;

BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MASTECTOMY;

EID: 67651205936     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.09.23     Document Type: Review

References (162)

1. March DE, Raslavicus A, Coughlin BF, Klein SV, Makari-Judson G: Use of breast core biopsy in the United States: results of a national survey. AJR Am. J. Roentgenol. 169(3), 697-701 (1997).
2. Jacobs TW, Connolly JL, Schnitt SJ: Nonmalignant lesions in breast core needle biopsies: to excise or not to excise? Am. J. Surg. Pathol. 26(9), 1095-1110 (2002).
3. Liberman L, Sama M, Susnik B et al.: Lobular carcinoma in situ at percutaneous breast biopsy: surgical biopsy findings. AJR Am. J. Roentgenol. 173(2), 291-299 (1999).
4. Guerra-Wallace MM, Christensen WN, White RL Jr: A retrospective study of columnar alteration with prominent apical snouts and secretions and the association with cancer. Am. J. Surg. 188(4), 395-398 (2004).
5. Kunju LP, Kleer CG: Significance of flat epithelial atypia on mammotome core needle biopsy: should it be excised? Hum. Pathol. 38(1), 35-41 (2007).
6. Antoniou AC, Easton DF: Models of genetic susceptibility to breast cancer. Oncogene 25(43), 5898-5905 (2006).
7. van't Veer LJ, Dai H, van de Vijver MJ et al.: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871), 530-536 (2002).
8. Schwartz GF, Hughes KS, Lynch HT et al.: Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007. Cancer 113(10), 2627-2637 (2008).
9. Nelson HD, Huffman LH, Fu R, Harris EL; US Preventive Services Task Force: Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the US Preventive Services Task Force. Ann. Intern. Med. 143(5), 362-379 (2005).
10. Hartmann LC, Schaid DJ, Woods JE et al.: Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N. Engl. J. Med. 340(2), 77-84 (1999).
11. Rebbeck TR, Friebel T, Lynch HT et al.: Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J. Clin. Oncol. 22(6), 1055-1062 (2004).
12. Kauff ND, Domchek SM, Friebel TM et al.: Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J. Clin. Oncol. 26(8), 1331-1337 (2008).
13. NIH consensus conference: Treatment of early-stage breast cancer. JAMA 265(3), 391-395 (1991).
14. Morris AD, Morris RD, Wilson JF et al.: Breast-conserving therapy vs mastectomy in early-stage breast cancer: a meta-analysis of 10-year survival. Cancer J. Sci. Am. 3(1), 6-12 (1997).
15. Fisher B, Anderson S, Bryant J et al.: Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N. Engl. J. Med. 347(16), 1233-1241(2002).
16. Veronesi U, Cascinelli N, Mariani L et al.: Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N. Engl. J. Med. 347(16), 1227-1232 (2002).
17. Poggi MM, Danforth DN, Sciuto LC et al.: Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized Trial. Cancer 98(4), 697-702 (2003).
18. van Dongen JA, Voogd AC, Fentiman IS et al.: Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J. Natl Cancer Inst. 92(14), 1143-1150 (2000).
19. Sarrazin D, Lê MG, Arriagada R et al.: Ten-year results of a randomized trial comparing a conservative treatment to mastectomy in early breast cancer. Radiother. Oncol. 14(3), 177-184 (1989).
20. Blichert-Toft M, Rose C, Andersen JA et al.: Danish randomized trial comparing breast conservation therapy with mastectomy: six years of life-table analysis. Danish Breast Cancer Cooperative Group. J. Natl Cancer Inst. Monogr. (11), 19-25 (1992).
21. van Dongen JA, Bartelink H, Fentiman IS et al.: Factors influencing local relapse and survival and results of salvage treatment after breast-conserving therapy in operable breast cancer: EORTC trial 10801, breast conservation compared with mastectomy in TNM stage I and II breast cancer. Eur. J. Cancer 28A(4-5), 801-805 (1992).
22. Leong C, Boyages J, Jayasinghe UW et al.: Effect of margins on ipsilateral breast tumor recurrence after breast conservation therapy for lymph node-negative breast carcinoma. Cancer 100(9), 1823-1832 (2004).
23. Park CC, Mitsumori M, Nixon A et al.: Outcome at 8 years after breast-conserving surgery and radiation therapy for invasive breast cancer: influence of margin status and systemic therapy on local recurrence. J. Clin. Oncol. 18(8), 1668-1675 (2000).
24. Schwartz GF, Veronesi U, Clough KB et al.: Proceedings of the consensus conference on breast conservation, April 28 to May 1, 2005, Milan, Italy. Cancer 107(2), 242-250 (2006).
25. Singletary SE: Surgical margins in patients with early-stage breast cancer treated with breast conservation therapy. Am. J. Surg. 184(5), 383-393 (2002).
26. Clarke M, Collins R, Darby S et al.: Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366(9503), 2087-2106 (2005).
27. White JR, Halberg FE, Rabinovitch R et al.: American college of radiology appropriateness criteria on conservative surgery and radiation: stages I and II breast carcinoma. J. Am. Coll. Radiol. 5(6), 701-713 (2008).
28. Aisenberg AC, Finkelstein DM, Doppke KP, Koerner FC, Boivin JF, Willett CG: High risk of breast carcinoma after irradiation of young women with Hodgkin's disease. Cancer 79(6), 1203-1210 (1997).
29. Chen AM, Obedian E, Haffty BG: Breast-conserving therapy in the setting of collagen vascular disease. Cancer J. 7(6), 480-491 (2001).
30. Carpenter S, Fraser J, Fleming M, Gray R, Halyard M, Pockaj B: Optimal treatment of multiple ipsilateral primary breast cancers. Am. J. Surg. 196(4), 530-536 (2008).
31. Cabioglu N, Hunt KK, Buchholz TA et al.: Improving local control with breast-conserving therapy: a 27-year single-institution experience. Cancer 104(1), 20-29 (2005).
32. Elkhuizen PH, van de Vijver MJ, Hermans J et al.: Local recurrence after breast-conserving therapy for invasive breast cancer: high incidence in young patients and association with poor survival. Int. J. Radiat. Oncol. Biol. Phys. 40(4), 859-867 (1998).
33. Vo TN, Meric-Bernstam F, Yi M et al.: Outcomes of breast-conservation therapy for invasive lobular carcinoma are equivalent to those for invasive ductal carcinoma. Am. J. Surg. 192(4), 552-555 (2006).
34. Pestalozzi BC, Zahrieh D, Mallon E et al.: Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J. Clin. Oncol. 26(18), 3006-3014 (2008).
35. Nguyen PL, Taghian AG, Katz MS et al.: Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J. Clin. Oncol. 26(14), 2373-2378 (2008).
36. Pierce LJ, Levin AM, Rebbeck TR et al.: Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J. Clin. Oncol. 24(16), 2437-2443 (2006).
37. Kirova YM, Stoppa-Lyonnet D, Savignoni A et al.: Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. Eur. J. Cancer 41(15), 2304-2311 (2005).
38. Metcalfe KA: Prophylactic bilateral mastectomy for breast cancer prevention. J. Womens Health (Larchmt) 13(7), 822-829 (2004).
39. Bassett LW, Dhaliwal SG, Eradat J et al.: National trends and practices in breast MRI. AJR Am. J. Roentgenol. 191(2), 332-339 (2008).
40. Houssami N, Ciatto S, Macaskill P et al.: Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: systematic review and meta-analysis in detection of multifocal and multicentric cancer. J. Clin. Oncol. 26(19), 3248-3258 (2008).
41. Lehman CD, Gatsonis C, Kuhl CK et al.: MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N. Engl. J. Med. 356(13), 1295-1303 (2007).
42. Solin LJ, Orel SG, Hwang WT, Harris EE, Schnall MD: Relationship of breast magnetic resonance imaging to outcome after breast-conservation treatment with radiation for women with early-stage invasive breast carcinoma or ductal carcinoma in situ. J. Clin. Oncol. 26(3), 386-391 (2008).
43. Goodwin PJ, Black JT, Bordeleau LJ, Ganz PA: Health-related quality-of-life measurement in randomized clinical trials in breast cancer - taking stock. J. Natl Cancer Inst. 95(4), 263-281 (2003).
44. de Haes JC, van Oostrom MA, Welvaart K: The effect of radical and conserving surgery on the quality of life of early breast cancer patients. Eur. J. Surg. Oncol. 12(4), 337-342 (1986).
45. Kemeny MM, Wellisch DK, Schain WS: Psychosocial outcome in a randomized surgical trial for treatment of primary breast cancer. Cancer 62(6), 1231-1237 (1988).
46. Levy SM, Herberman RB, Lee JK, Lippman ME, d'Angelo T: Breast conservation versus mastectomy: distress sequelae as a function of choice. J. Clin. Oncol. 7(3), 367-375 (1989).
47. Poulsen B, Graversen HP, Beckmann J, Blichert-Toft M: A comparative study of post-operative psychosocial function in women with primary operable breast cancer randomized to breast conservation therapy or mastectomy. Eur. J. Surg. Oncol. 23(4), 327-334 (1997).
48. Curran D, van Dongen JP, Aaronson NK et al.: Quality of life of early-stage breast cancer patients treated with radical mastectomy or breast-conserving procedures: results of EORTC Trial 10801 The European organization for research and treatment of cancer (EORTC), Breast cancer co-operative group (BCCG). Eur. J. Cancer 34(3), 307-314 (1998).
49. Parker PA, Youssef A, Walker S et al.: Short-term and long-term psychosocial adjustment and quality of life in women undergoing different surgical procedures for breast cancer. Ann. Surg. Oncol. 14(11), 3078-3089 (2007).
50. Katz SJ, Lantz PM, Janz NK et al.: Surgeon perspectives about local therapy for breast carcinoma. Cancer 104(9), 1854-1861 (2005).
51. White J, Morrow M, Moughan J et al.: Compliance with breast-conservation standards for patients with early-stage breast carcinoma. Cancer 97(4), 893-904 (2003).
52. Chagpar AB, Studts JL, Scoggins CR et al.: Factors associated with surgical options for breast carcinoma. Cancer 106(7), 1462-1466 (2006).
53. Clough KB, Cuminet J, Fitoussi A, Nos C, Mosseri V: Cosmetic sequelae after conservative treatment for breast cancer: classification and results of surgical correction. Ann. Plast. Surg. 41(5), 471-481 (1998).
54. Hughes JH, Mason MC, Gray RJ et al.: A multi-site validation trial of radioactive seed localization as an alternative to wire localization. Breast J. 14(2), 153-157 (2008).
55. Burkholder HC, Witherspoon LE, Burns RP, Horn JS, Biderman MD: Breast surgery techniques: preoperative bracketing wire localization by surgeons. Am. Surg. 73(6), 574-578; discussion 578-579 (2007).
56. Losken A, Styblo TM, Carlson GW, Jones GE, Amerson BJ: Management algorithm and outcome evaluation of partial mastectomy defects treated using reduction or mastopexy techniques. Ann. Plast. Surg. 59(3), 235-242 (2007).
57. McLaughlin SA, Ochoa-Frongia LM, Patil SM, Cody HS 3rd, Sclafani LM: Influence of frozen-section analysis of sentinel lymph node and lumpectomy margin status on reoperation rates in patients undergoing breast-conservation therapy. J. Am. Coll. Surg. 206(1), 76-82 (2008).
58. Velanovich V, Lewis FR Jr, Nathanson SD et al.: Comparison of mammographically guided breast biopsy techniques. Ann. Surg. 229(5), 625-630; discussion 630-633 (1999).
59. O'Sullivan MJ, Li T, Freedman G, Morrow M: The effect of multiple reexcisions on the risk of local recurrence after breast conserving surgery. Ann. Surg. Oncol. 14(11), 3133-3140 (2007).
60. Thompson M, Henry-Tillman R, Margulies A et al.: Hematoma-directed ultrasound-guided (HUG) breast lumpectomy. Ann. Surg. Oncol. 14(1), 148-156 (2007).
61. Kaufman CS, Jacobson L, Bachman B, Kaufman LB: Intraoperative ultrasonography guidance is accurate and efficient according to results in 100 breast cancer patients. Am. J. Surg. 186(4), 378-382 (2003).
62. Ngô C, Pollet AG, Laperrelle J et al.: Intraoperative ultrasound localization of nonpalpable breast cancers. Ann. Surg. Oncol. 14(9), 2485-2489 (2007).
63. Fortunato L, Penteriani R, Farina M, Vitelli CE, Piro FR: Intraoperative ultrasound is an effective and preferable technique to localize non-palpable breast tumors. Eur. J. Surg. Oncol. 34(12), 1289-1292 (2008).
64. Gray RJ, Pockaj BA, Karstaedt PJ, Roarke MC: Radioactive seed localization of nonpalpable breast lesions is better than wire localization. Am. J. Surg. 188(4), 377-380 (2004).
65. Layeequr Rahman R, Iuanow E, Crawford S, Quinlan R: Sonographic hematoma-guided vs wire-localized lumpectomy for breast cancer: a comparison of margins and volume of resection. Arch. Surg. 142(4), 343-346 (2007).
66. Garvey PB, Buchel EW, Pockaj BA, Gray RJ, Samson TD: The deep inferior epigastric perforator flap for breast reconstruction in overweight and obese patients. Plast. Reconstr. Surg. 115(2), 447-457 (2005).
67. Garvey PB, Buchel EW, Pockaj BA et al.: DIEP and pedicled TRAM flaps: a comparison of outcomes. Plast. Reconstr. Surg. 117(6), 1711-1719; discussion 1720-1721 (2006).
68. Pomahac B, Recht A, May JW, Hergrueter CA, Slavin SA: New trends in breast cancer management: is the era of immediate breast reconstruction changing? Ann. Surg. 244(2), 282-288 (2006).
69. Carlson GW: Skin sparing mastectomy: anatomic and technical considerations. Am. Surg. 62(2), 151-155 (1996).
70. Simmons RM, Fish SK, Gayle L et al.: Local and distant recurrence rates in skin-sparing mastectomies compared with non-skin-sparing mastectomies. Ann. Surg. Oncol. 6(7), 676-681 (1999).
71. Stolier AJ, Sullivan SK, Dellacroce FJ: Technical considerations in nipple-sparing mastectomy: 82 consecutive cases without necrosis. Ann. Surg. Oncol. 15(5), 1341-1347 (2008).
72. Garwood ER, Moore D, Ewing C et al.: Total skin-sparing mastectomy: complications and local recurrence rates in 2 cohorts of patients. Ann. Surg. 249(1), 26-32 (2009).
73. Sacchini V, Pinotti JA, Barros AC et al.: Nipple-sparing mastectomy for breast cancer and risk reduction: oncologic or technical problem? J. Am. Coll. Surg. 203(5), 704-714 (2006).
74. Gerber B, Krause A, Reimer T et al.: Skin-sparing mastectomy with conservation of the nipple-areola complex and autologous reconstruction is an oncologically safe procedure. Ann. Surg. 238(1), 120-127 (2003).
75. Tuttle T, Habermann E, Abraham A, Emory T, Virnig B: Contralateral prophylactic mastectomy for patients with unilateral breast cancer. Expert Rev. Anticancer Ther. 7(8), 1117-1122 (2007).
76. Giuliano AE, Boolbol S, Degnim A, Kuerer H, Leitch AM, Morrow M: Society of Surgical Oncology: position statement on prophylactic mastectomy. Approved by the Society of Surgical Oncology Executive Council, March 2007. Ann. Surg. Oncol. 14(9), 2425-2427(2007).
77. Quan, G, Pommier SJ, Pommier RF: Incidence and outcomes of contralateral breast cancers. Am. J. Surg. 195(5), 645-650; discussion 650 (2008).
78. Hill-Kayser CE, Harris EE, Hwang WT, Solin LJ: Twenty-year incidence and patterns of contralateral breast cancer after breast conservation treatment with radiation. Int. J. Radiat. Oncol. Biol. Phys. 66(5), 1313-1319 (2006).
79. Lostumbo L, Carbine N, Wallace J, Ezzo J: Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst. Rev. (4), CD002748 (2004)
80. Chung MA, Cole B, Wanebo HJ, Bland KI, Chang HR: Optimal surgical treatment of invasive lobular carcinoma of the breast. Ann. Surg. Oncol. 4(7), 545-550 (1997).
81. Yeatman TJ, Lyman GH, Smith SK, Reintgen DS, Cantor AB, Cox CE: Bilaterality and recurrence rates for lobular breast cancer: considerations for treatment. Ann. Surg. Oncol. 4(3), 198-202 (1997).
82. Loibl S, von Minckwitz G, Gwyn K et al.: Breast carcinoma during pregnancy. International recommendations from an expert meeting. Cancer 106(2), 237-246 (2006).
83. Antonelli NM, Dotters DJ, Katz VL, Kuller JA: Cancer in pregnancy: a review of the literature. Part II. Obstet. Gynecol. Surv. 51(2), 135-142 (1996).
84. Antonelli NM, Dotters DJ, Katz VL, Kuller JA: Cancer in pregnancy: a review of the literature. Part I. Obstet. Gynecol. Surv. 51(2), 125-134 (1996).
85. Middleton LP, Amin M, Gwyn K, Theriault R, Sahin A: Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features. Cancer 98(5), 1055-1060 (2003).
86. Melnick DM, Wahl WL, Dalton VK: Management of general surgical problems in the pregnant patient. Am. J. Surg. 187(2), 170-180 (2004).
87. Woo JC, Yu T, Hurd TC: Breast cancer in pregnancy: a literature review. Arch. Surg. 138(1), 91-98; discussion 99 (2003).
88. Schackmuth EM, Harlow CL, Norton LW: Milk fistula: a complication after core breast biopsy. AJR Am. J. Roentgenol. 161(5), 961-962 (1993).
89. Kal HB, Struikmans H: Breast carcinoma during pregnancy. International recommendations from an expert meeting. Cancer 107(4), 882-883; author reply 883 (2006).
90. Gentilini O, Cremonesi M, Trifirò G et al.: Safety of sentinel node biopsy in pregnant patients with breast cancer. Ann. Oncol. 15(9), 1348-1351 (2004).
91. Pandit-Taskar N, Dauer LT, Montgomery L, St Germain J, Zanzonico PB, Divgi CR: Organ and fetal absorbed dose estimates from 99mTc-sulfur colloid lymphoscintigraphy and sentinel node localization in breast cancer patients. J. Nucl. Med. 47(7), 1202-1208 (2006).
92. Mondi MM, Cuenca RE, Ollila DW, Stewart JH 4th, Levine EA: Sentinel lymph node biopsy during pregnancy: initial clinical experience. Ann. Surg. Oncol. 14(1), 218-221 (2007).
93. Krontiras H, Bland KI: When is sentinel node biopsy for breast cancer contraindicated? Surg. Oncol. 12(3), 207-210 (2003).
94. Berry DL, Theriault RL, Holmes FA et al.: Management of breast cancer during pregnancy using a standardized protocol. J. Clin. Oncol. 17(3), 855-861 (1999).
95. Gwyn K: Children exposed to chemotherapy in utero. J. Natl Cancer Inst. Monogr. (34), 69-71 (2005).
96. Ebert, U, Loffler H, Kirch W: Cytotoxic therapy and pregnancy. Pharmacol. Ther. 74(2), 207-220 (1997).
97. Doll DC, Ringenberg QS, Yarbro JW: Antineoplastic agents and pregnancy. Semin. Oncol. 16(5), 337-346 (1989).
98. Cardonick, E. Iacobucci A: Use of chemotherapy during human pregnancy. Lancet Oncol. 5(5), 283-291 (2004).
99. Ring AE, Smith IE, Jones A, Shannon C, Galani E, Ellis PA: Chemotherapy for breast cancer during pregnancy: an 18-year experience from five London teaching hospitals. J. Clin. Oncol. 23(18), 4192-4197 (2005).
100. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B: Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J. Natl Cancer Inst. Monogr. (30), 96-102 (2001).
101. van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L: Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J. Clin. Oncol. 19(22), 4224-4237 (2001).
102. Mauri, D, Pavlidis N, Ioannidis JP: Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J. Natl Cancer Inst. 97(3), 188-194 (2005).
103. Chen AM, Meric-Bernstam F, Hunt KK et al.: Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J. Clin. Oncol. 22(12), 2303-2312 (2004).
104. Huang EH, Strom EA, Perkins GH et al.: Comparison of risk of local-regional recurrence after mastectomy or breast conservation therapy for patients treated with neoadjuvant chemotherapy and radiation stratified according to a prognostic index score. Int. J. Radiat. Oncol. Biol. Phys. 66(2), 352-357 (2006).
105. Rouzier R, Extra JM, Carton M et al.: Primary chemotherapy for operable breast cancer: incidence and prognostic significance of ipsilateral breast tumor recurrence after breast-conserving surgery. J. Clin. Oncol. 19(18), 3828-3835 (2001).
106. Shen J, Gilcrease MZ, Babiera GV et al.: Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases. Cancer 109(7), 1255-1263 (2007).
107. Newman EA, Sabel MS, Nees AV et al.: Sentinel lymph node biopsy performed after neoadjuvant chemotherapy is accurate in patients with documented node-positive breast cancer at presentation. Ann. Surg. Oncol. 14(10), 2946-2952 (2007).
108. Hinson JL, McGrath P, Moore A et al.: The critical role of axillary ultrasound and aspiration biopsy in the management of breast cancer patients with clinically negative axilla. Ann. Surg. Oncol. 15(1), 250-255 (2008).
109. Veronesi U, Paganelli G, Viale G et al.: A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N. Engl. J. Med. 349(6), 546-553 (2003).
110. Krag DN, Julian TB, Harlow SP et al.: NSABP-32: Phase III, randomized trial comparing axillary resection with sentinal lymph node dissection: a description of the trial. Ann. Surg. Oncol. 11(Suppl. 3), 208S-210S (2004).
111. Jain A, Haisfield-Wolfe ME, Lange J et al.: The role of ultrasound-guided fine-needle aspiration of axillary nodes in the staging of breast cancer. Ann. Surg. Oncol. 15(2), 462-471 (2008).
112. McMasters KM, Tuttle TM, Carlson DJ et al.: Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J. Clin. Oncol. 18(13), 2560-2566 (2000).
113. McMasters KM et al.: Preoperative lymphoscintigraphy for breast cancer does not improve the ability to identify axillary sentinel lymph nodes. Ann. Surg. 231(5), 724-731 (2000).
114. Gray RJ, Pockaj BA: A concordance study of subareolar and subdermal injections for breast cancer sentinel lymph node mapping. Am. J. Surg. 188(4), 423-425 (2004).
115. Tousimis E, Van Zee KJ, Fey JV et al.: The accuracy of sentinel lymph node biopsy in multicentric and multifocal invasive breast cancers. J. Am. Coll. Surg. 197(4), 529-535 (2003).
116. Gentilini O, Trifirò G, Soteldo J et al.: Sentinel lymph node biopsy in multicentric breast cancer. The experience of the European Institute of Oncology. Eur. J. Surg. Oncol. 32(5), 507-510 (2006).
117. Gray RJ, Forstner-Barthell AW, Pockaj BA, Schild SE, Halyard MY: Breast-conserving therapy and sentinel lymph node biopsy are feasible in cancer patients with previous implant breast augmentation. Am. J. Surg.
118. Port ER, Fey J, Gemignani ML et al.: Reoperative sentinel lymph node biopsy: a new option for patients with primary or locally recurrent breast carcinoma. J. Am. Coll. Surg. 195(2), 167-172 (2002).
119. Intra M, Trifirò G, Viale G et al.: Second biopsy of axillary sentinel lymph node for reappearing breast cancer after previous sentinel lymph node biopsy. Ann. Surg. Oncol. 12(11), 895-899 (2005).
120. Jones JL, Zabicki K, Christian RL et al.: A comparison of sentinel node biopsy before and after neoadjuvant chemotherapy: timing is important. Am. J. Surg. 190(4), 517-520 (2005).
121. Cox CE, Cox JM, White LB et al.: Sentinel node biopsy before neoadjuvant chemotherapy for determining axillary status and treatment prognosis in locally advanced breast cancer. Ann. Surg. Oncol. 13(4), 483-490 (2006).
122. Fisher B, Brown A, Mamounas E et al.: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J. Clin. Oncol. 15(7), 2483-2493 (1997).
123. Kuerer HM, Newman LA, Smith TL et al.: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J. Clin. Oncol. 17(2), 460-469 (1999).
124. Bear HD, Anderson S, Brown A et al.: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J. Clin. Oncol. 21(22), 4165-4174 (2003).
125. Mamounas EP, Brown A, Anderson S et al.: Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J. Clin. Oncol. 23(12), 2694-2702 (2005).
126. Xing Y, Foy M, Cox DD, Kuerer HM, Hunt KK, Cormier JN: Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br. J. Surg. 93(5), 539-546 (2006).
127. Babiera GV, Rao R, Feng L et al.: Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann. Surg. Oncol. 13(6), 776-782 (2006).
128. Khan SA, Stewart AK, Morrow M: Does aggressive local therapy improve survival in metastatic breast cancer? Surgery 132(4), 620-626; discussion 626-627 (2002).
129. Gnerlich J, Jeffe DB, Deshpande AD, Beers C, Zander C, Margenthaler JA: Surgical removal of the primary tumor increases overall survival in patients with metastatic breast cancer: analysis of the 1988-2003 SEER data. Ann. Surg. Oncol. 14(8), 2187-2194 (2007).
130. Rapiti E, Verkooijen HM, Vlastos G et al.: Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J. Clin. Oncol. 24(18), 2743-2749 (2006).
131. Adam R, Aloia T, Krissat J et al.: Is liver resection justified for patients with hepatic metastases from breast cancer? Ann. Surg. 244(6), 897-907; discussion 907-908 (2006).
132. Elias D, Maisonnette F, Druet-Cabanac M et al.: An attempt to clarify indications for hepatectomy for liver metastases from breast cancer. Am. J. Surg. 185(2), 158-164 (2003).
133. Planchard D, Soria JC, Michiels S et al.: Uncertain benefit from surgery in patients with lung metastases from breast carcinoma. Cancer 100(1), 28-35 (2004).
134. Friedel G, Pastorino U, Ginsberg RJ et al.: Results of lung metastasectomy from breast cancer: prognostic criteria on the basis of 467 cases of the International Registry of Lung Metastases. Eur. J. Cardiothorac. Surg. 22(3), 335-344 (2002).
135. Cuttino LW, Keisch M, Jenrette JM et al.: Multi-institutional experience using the MammoSite radiation therapy system in the treatment of early-stage breast cancer: 2-year results. Int. J. Radiat. Oncol. Biol. Phys. 71(1), 107-114 (2008).
136. Chao KK, Vicini FA, Wallace M et al.: Analysis of treatment efficacy, cosmesis, and toxicity using the MammoSite breast brachytherapy catheter to deliver accelerated partial-breast irradiation: the william beaumont hospital experience. Int. J. Radiat. Oncol. Biol. Phys. 69(1), 32-40 (2007).
137. Jeruss JS, Vicini FA, Beitsch PD et al.: Initial outcomes for patients treated on the American Society of Breast Surgeons MammoSite clinical trial for ductal carcinoma-in-situ of the breast. Ann. Surg. Oncol. 13(7), 967-976 (2006).
138. Huston TL, Simmons RM: Locally recurrent breast cancer after conservation therapy. Am. J. Surg. 189(2), 229-235 (2005).
139. Fisher B, Anderson S, Fisher ER et al.: Significance of ipsilateral breast tumour recurrence after lumpectomy. Lancet 338(8763), 327-331 (1991).
140. Osborne MP, Simmons RM: Salvage surgery for recurrence after breast conservation. World J. Surg. 18(1), 93-97 (1994).
141. Hughes KS et al.: Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N. Engl. J. Med. 351(10), 971-977 (2004).
142. Solin LJ, Fourquet A, Vicini FA et al.: Salvage treatment for local recurrence after breast-conserving surgery and radiation as initial treatment for mammographically detected ductal carcinoma in situ of the breast. Cancer 91(6), 1090-1097 (2001).
143. Recht A, Schnitt SJ, Connolly JL et al.: Prognosis following local or regional recurrence after conservative surgery and radiotherapy for early stage breast carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 16(1), 3-9 (1989).
144. Abner AL, Recht A, Eberlein T et al.: Prognosis following salvage mastectomy for recurrence in the breast after conservative surgery and radiation therapy for early-stage breast cancer. J. Clin. Oncol. 11(1), 44-48 (1993).
145. Kuerer HM, Arthur DW, Haffty BG: Repeat breast-conserving surgery for in-breast local breast carcinoma recurrence: the potential role of partial breast irradiation. Cancer 100(11), 2269-2280 (2004).
146. Buchanan CL, Dorn PL, Fey J et al.: Locoregional recurrence after mastectomy: incidence and outcomes. J. Am. Coll. Surg. 203(4), 469-474 (2006).
147. Chagpar A, Meric-Bernstam F, Hunt KK et al.: Chest wall recurrence after mastectomy does not always portend a dismal outcome. Ann. Surg. Oncol. 10(6), 628-634 (2003).
148. Gimbergues P, Abrial C, Durando X et al.: Sentinel lymph node biopsy after neoadjuvant chemotherapy is accurate in breast cancer patients with a clinically negative axillary nodal status at presentation. Ann. Surg. Oncol. 15(5), 1316-1321 (2008).
149. Papa MZ, Zippel D, Kaufman B et al.: Timing of sentinel lymph node biopsy in patients receiving neoadjuvant chemotherapy for breast cancer. J. Surg. Oncol. 98(6), 403-406 (2008).
150. Kinoshita T, Takasugi M, Iwamoto E, Akashi-Tanaka S, Fukutomi T, Terui S: Sentinel lymph node biopsy examination for breast cancer patients with clinically negative axillary lymph nodes after neoadjuvant chemotherapy. Am. J. Surg. 191(2), 225-229 (2006).
151. Patel NA, Piper G, Patel JA, Malay MB, Julian TB: Accurate axillary nodal staging can be achieved after neoadjuvant therapy for locally advanced breast cancer. Am. Surg. 70(8), 696-699; discussion 699-700 (2004).
152. Shimazu K, Tamaki Y, Taguchi T, Akazawa K, Inoue T, Noguchi S: Sentinel lymph node biopsy using periareolar injection of radiocolloid for patients with neoadjuvant chemotherapy-treated breast carcinoma. Cancer 100(12), 2555-2561 (2004).
153. Lang JE, Esserman LJ, Ewing CA et al.: Accuracy of selective sentinel lymphadenectomy after neoadjuvant chemotherapy: effect of clinical node status at presentation. J. Am. Coll. Surg. 199(6), 856-862 (2004).
154. Schwartz GF, Meltzer AJ: Accuracy of axillary sentinel lymph node biopsy following neoadjuvant (induction) chemotherapy for carcinoma of the breast. Breast J. 9(5), 374-379 (2003).
155. Miller AR, Thomason VE, Yeh IT et al.: Analysis of sentinel lymph node mapping with immediate pathologic review in patients receiving preoperative chemotherapy for breast carcinoma. Ann. Surg. Oncol. 9(3), 243-247 (2002).
156. Stearns V, Ewing CA, Slack R, Penannen MF, Hayes DF, Tsangaris TN: Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. Ann. Surg. Oncol. 9(3), 235-242 (2002).
157. Haid A, Tausch C, Lang A et al.: Is sentinel lymph node biopsy reliable and indicated after preoperative chemotherapy in patients with breast carcinoma? Cancer 92(5), 1080-1084 (2001).
158. Tafra, L, Verbanac KM, Lannin DR: Preoperative chemotherapy and sentinel lymphadenectomy for breast cancer. Am. J. Surg. 182(4), 312-315 (2001).
159. Fernández A, Cortés M, Benito E et al.: γ probe sentinel node localization and biopsy in breast cancer patients treated with a neoadjuvant chemotherapy scheme. Nucl. Med. Commun. 22(4), 361-366 (2001).
160. Julian TB, Patel N, Dusi D et al.: Sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer. Am. J. Surg. 182(4), 407-410 (2001).
161. Breslin TM, Cohen L, Sahin A et al.: Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J. Clin. Oncol. 18(20), 3480-3486 (2000).
162. Nason KS, Anderson BO, Byrd DR et al.: Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma. Cancer 89(11), 2187-2194 (2000).